RxDoctor Payments Data

Craig Erickson, MD

Child & Adolescent Psychiatry · Cincinnati, OHNPI 1770789273

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,240 of the $9,304 with a category attached, or 99.3%. 5 manufacturers reported payments, led by Mirum Pharmaceuticals, Inc. at 58.0% of the total. 2025 is the largest year on record at $3,600, more than ten times the $36 reported in 2019. Among child & adolescent psychiatry clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,304in general payments, 2019–2025

Across 6 payments — averaging $1550.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirum Pharmaceuticals, Inc.$5K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • Alkermes, Inc.$2K
  • Merck$36
  • Impel Pharmaceuticals Inc.$28
$266,115in research payments, 2019–2025

Across 34 payments — averaging $7826.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$266K

What the payments were for

  • Consulting fees$9,24099%
  • Food & beverage$641%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,304 in reported general payments places this provider in the 90th percentile of 160 child & adolescent psychiatry providers in Ohio.

See all child & adolescent psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$3,702
Medicare patients
14
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate42$211,312
RybelsusSemaglutide58$58,684
Paliperidone ErPaliperidone92$33,551
Aripiprazole114$24,264
MounjaroTirzepatide21$21,787
Chlorpromazine Hcl46$20,531
BelsomraSuvorexant26$12,154
Acamprosate Calcium60$8,269
Ziprasidone Hcl33$6,123
Quetiapine Fumarate ErQuetiapine Fumarate17$5,965
Divalproex Sodium ErDivalproex Sodium26$2,629
Buspirone Hcl25$2,391
Fluvoxamine Maleate46$2,028
Divalproex Sodium39$1,961
Temazepam30$1,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckBelsomra$36$12,15426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 160 child & adolescent psychiatry providers in Ohio.

Other child & adolescent psychiatry in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →